| Code | CSB-RA004929MB12HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to SCT-C21, targeting CD38, a multifunctional type II transmembrane glycoprotein with both enzymatic and receptor functions. CD38 catalyzes the synthesis and hydrolysis of cyclic ADP-ribose and ADP-ribose from NAD+, playing crucial roles in calcium signaling, cell adhesion, and signal transduction. This protein is widely expressed on immune cells including plasma cells, activated T cells, B cells, and natural killer cells, and exhibits significantly elevated expression in various hematological malignancies, particularly multiple myeloma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia.
SCT-C21 serves as a reference antibody in studies investigating CD38 biology and therapeutic mechanisms. This biosimilar provides researchers with a reliable tool for exploring CD38-mediated pathways in immune regulation, cancer biology, and metabolic processes. The antibody is valuable for investigating CD38's role in tumor microenvironments, evaluating immune cell populations, and studying the molecular mechanisms underlying hematological disorders and immunological responses.
There are currently no reviews for this product.